Friedberg Ezra M
Known title: DirectorCIK: 0001679440
Associated companies
Transaction History
| PTHS | ▼ Sell | Open Market | 558 | $12K | 10/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 534 | $14K | 7/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 24 | $656 | 7/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 224 | $6K | 6/15/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 59 | $2K | 6/15/2026 | View on chart |
| PTHS | ▼ Sell | Tax Withholding | 144 | $4K | 5/14/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 293 | $6K | 4/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 265 | $6K | 4/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 5,999 | $168K | 11/25/2025 | View on chart |
| PTHS | ▼ Sell | Open Market | 2,000 | $56K | 11/25/2025 | View on chart |
| PTHS | ▼ Sell | Open Market | 1 | $29 | 11/25/2025 | View on chart |
| PTHS | ▼ Sell | Open Market | 2,000 | $56K | 11/25/2025 | View on chart |
| PTHS | ▼ Sell | Other | 40,000 | $400K | 7/1/2025 | View on chart |
| PTHS | ▼ Sell | Other | 40,000 | $400K | 7/1/2025 | View on chart |
| PTHS | ▲ Buy | Option Exercise | 6,992 | $34K | 2/21/2024 | View on chart |
| PTHS | ▲ Buy | Option Exercise | 13,649 | $66K | 2/21/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Pelthos Expands Coverage for ZELSUVMI Topical Gel
Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.
Pelthos Expands Coverage for ZELSUVMI Topical Gel. Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.